GNB5 loss-of-function pathogenic variants cause IDDCA, a rare autosomal recessive human genetic disease characterized by infantile onset of intellectual disability, sinus bradycardia, hypotonia, visual abnormalities, and epilepsy. We generated human induced pluripotent stem cells (hiPSCs) from skin fibroblasts of a patient with the homozygous c.136delG frameshift variant, and a GNB5 knock-out (KO) line by CRISPR/Cas9 editing. hiPSCs express common pluripotency markers and differentiate into the three germ layers. These lines represent a powerful cellular model to study the molecular basis of GNB5-related disorders as well as offer an in vitro model for drug screening.
Resource utility
hiPSC lines offer the opportunity to produce large amount of patient-specific and GNB5 knock-out cells, and to differentiate them into cell types relevant to the GNB5 disorders, like cardiomyocytes and neurons. Their characterization will give insights on the disorder pathogenesis and offer a powerful in vitro model for drug screening.
Resource details
Bi-allelic non-sense and frameshift mutations in the GNB5 gene, encoding the β5 subunit of heterotrimeric G-proteins (Gβ5), are associated with the autosomal-recessive multisystem syndrome named Intellectual Developmental Disorder with Cardiac Arrhythmia (IDDCA; MIM#617173) (Lodder et al., 2016) . This syndrome is characterized by intellectual disability, developmental and epileptic encephalopathy, retinal abnormalities and early-onset sinus node dysfunction (with bradycardia). Bi-allelic GNB5 missense variants correlate with a milder manifestation of the disorder, characterized by language delay, attention-deficit/hyperactivity disorder, and mild cognitive impairment with or without cardiac arrhythmia (LADCI; MIM#617182) (Shamseldin et al., 2016) . The biological mechanisms underlying this syndrome are unclear. In order to elucidate how loss of Gβ5 activity affects functional properties of excitable cells involved in the syndrome, such as cardiomyocytes and neurons, the availability of an unlimited source of these fully differentiated cell types is a major requirement.
Here we report the generation of: (i) a hiPSC line from a 10-yearsold male proband carrying the c.136delG (p.E46fs8X) homozygous frameshift GNB5 mutation and (ii) an hiPSC line, from a healthy donor, in which we selectively knocked-out (KO) GNB5.
hiPSCs were generated from skin fibroblasts by the mRNA-based reprogramming method to generate integration free, virus-free hiPSCs, using a single transfection step (Simplicon™ RNA Reprogramming Kit; Merck-Millipore). The first colonies appeared 10 days after transfection and displayed the classical pluripotent stem cell morphology ( Supplementary Fig. 1A ). The hiPSC control line was handled for genome editing by CRISPR/Cas9; a clone with the homozygous GNB5 frameshift variant c.204_208delCATGG was selected and amplified (Table 1 ).
The expression of pluripotency genes (NANOG, OCT4, LIN28, REX1, SOX2, and GAPDH as reference gene), assessed by RT-qPCR, was higher in both the hiPSC lines than in the fibroblast of origin ( Fig. 1A ). Protein https://doi.org/10.1016/j.scr.2019.101547 Received 30 July 2019; Received in revised form 13 August 2019; Accepted 20 August 2019 expression of NANOG, OCT4, SOX2 and TRA-1-60 was also assessed by Immunocytochemistry ( Fig. 1B) . Moreover, quantitative flow cytometry analysis revealed that between 85.3 %and 99.4% of the cells of both hiPSC lines expressed the pluripotency markers SOX2 and SSEA-4 ( Fig. 1C) .
We then confirmed that both hiPSC lines were able to generate cells belonging to the three germ layers, as demonstrated by the positive expression of mesodermal (CD31, SMA), endodermal (SOX7, AFP), and ectodermal (KTR14, NCAM1) markers ( Fig. 1D ), achieved by RT-qPCR using β-actin as reference gene to normalize the expression of differentiation markers. The hiPSC lines showed a normal karyotype (Supplementary Fig. 1B ) and presented the expected mutations in GNB5 gene ( Fig. 1E ). Genetic DNA fingerprinting was performed for both hiPSC lines and their fibroblast counterparts, confirming their genetic identity ( Table 2 ). All hiPSC lines were negative for mycoplasma contamination ( Supplementary Fig. 1C ).
Materials and methods

Cell culture and reprogramming
Skin biopsies from an IDDCA patient and a healthy individual were used to establish primary dermal fibroblast cultures. For primary fibroblasts reprogramming, the Oct4, Klf4, Sox2, and Glis1 transgenes were expressed by Simplicon™ RNA Reprogramming Kit (Merck-Millipore), following the manufacturer's instructions. On day 28, individual hiPSC colonies were picked and growth on Matrigel™ (Corning) in TeSR-E8 medium and propagated using ReLeSR (Stem Cell Technologies) medium at 37°C and 5% CO 2 .
Generation of hiPSC GNB5 Knock-out through CRISPR/Cas9
Healthy control hiPSCs were transiently transfected with 2 μg of Gβ5 CRISPR/Cas9 KO Plasmids (Santa Cruz). After 48 h, GFP positive transfected cells were enriched by FACS analysis and dispersed at low density into Matrigel-coated 10 cm 2 dishes in TeSR-E8 Medium containing 5 μM ROCK inhibitor. After approximately 20 days, largest colonies were picked and expanded. Each clone was analysed for the GNB5 variants by Sanger Sequencing. A positive clone was selected and further analysed.
Mycoplasma test
Mycoplasma contamination was ruled out by PCR using primers able to recognize most of the Mycoplasma species ( Supplementary  Fig. 1C ). The 500 bp PCR product size was carried out by iCycler (Bio-Rad, USA) using the following PCR steps: 1. Denaturation at 95°C for 5 min; 2. Denaturation at 95°C for 30 s; 3. Primer annealing at 38°C for 30 s; 4. Primer extension at 72°C for 1 min; 5. Primer extension at 72°C for 10 min. Steps 2 to 4 was repeated 35 times.
Karyotype analysis
Cytogenetic G-banding analysis was performed on indicated cells ( Supplementary Fig. 1B ) at passage number 12, as previously described (Drets and Shaw, 1971) . Twenty metaphases were counted and three karyotypes were visualized with a 1000× objective (Zeiss, Germany) and analysed by G-banding at GAG 300-400 band resolution on average, using Applied Imaging Cito-Vision (Version 7.5).
Genotyping, sequencing, and STR analysis
Genomic DNA was extracted using Allprep DNA/RNA Mini kit (Qiagen) and GNB5 confirmed by Sanger sequencing (Fig. 1E ; Table 3 ). For STR analysis, we used the Promega PowerPlex 16 PCR kit (Promega, USA) that analysed 16 loci (Table 2) .
RNA isolation and quantitative RT-PCR (RT-qPCR)
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Germany). QuantiTect Reverse Transcription Kit (Qiagen) was used to carry out cDNA synthesis. cDNA was amplified using Power SYBR Green PCR Master Mix (Applied biosystem) on ABI PRISM 7009HT System (Table 3) .
Immunofluorescence staining
The hiPSCs were fixed in 4% paraformaldehyde for 15 min at room temperature (RT). Fixed cells were permeabilized and blocked for 30 min at RT with PBS containing 10% donkey serum (Jackson ImmunoResearch) and 0.1% TritonX-100 (VWR). Cells were then incubated with primary antibodies for 2 h at RT in 10% donkey serum in PBS. The secondary antibodies were thereafter added for 1 h at RT in the dark, followed by nuclei counterstain with DAPI. Images were acquired on an Inverted Fluorescence Microscope (Axiovert 200 M, Zeiss Carl; Software: AxioVision release 4.7.2 Dec 2008).
Flow cytometry
Flow Cytometry analysis was performed using Multi-Color Flow Cytometry Kit (R&D System) following manufacturer's instruction. Samples were analysed using FACSAria™ flow cytometry (BD Biosciences).
In vitro differentiation by embryoid body (EB) formation
Embryoid bodies (EBs) were formed from iPSCs detached and grown in ultra-low attachment plates (Corning) for 7 days in DMEM-F12 with 20% fetal bovine serum, 1 mM NEAAs, 2 mM L-Glutamine, 1% penicillin-Streptomycin and 0.1 mM β-mercaptoethanol. EBs were then seeded onto 0.1% gelatin-coated dishes for further 10 days of differentiation and analysed by RT-qPCR for endodermal, mesodermal, and ectodermal genes. Supplementary data to this article can be found online at https:// doi.org/10.1016/j.scr.2019.101547.
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